Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA

Stefan Worgall, Dolan Sondhi, Neil R. Hackett, Barry Kosofsky, Minal V. Kekatpure, Nurunisa Neyzi, Jonathan P. Dyke, Douglas Ballon, Linda Heier, Bruce M. Greenwald, Paul Christos, Madhu Mazumdar, Mark M. Souweidane, Michael G. Kaplitt, Ronald Crystal

Research output: Contribution to journalArticle

268 Citations (Scopus)

Abstract

Late infantile neuronal ceroid lipofuscinosis (LINCL) is an autosomal recessive, neurodegenerative lysosomal storage disease affecting the CNS and is fatal by age 8 to 12 years. A total average dose of 2.5 × 1012 particle units of an adeno-associated virus (AAV) serotype 2 vector expressing the human CLN2 cDNA (AAV2CU hCLN2) was administered to 12 locations in the CNS of 10 children with LINCL. In addition to safety parameters, a neurological rating scale (primary variable) and three quantitative magnetic resonance imaging (MRI) parameters (secondary variables) were used to compare the rate of neurological decline for 18 months in treated subjects compared with untreated subjects. Although there were no unexpected serious adverse events that were unequivocally attributable to the AAV2CU hCLN2 vector, there were serious adverse effects, the etiology of which could not be determined under the conditions of the experiment. One subject died 49 days postsurgery after developing status epilepticus on day 14, but with no evidence of CNS inflammation. Four of the 10 subjects developed a mild, mostly transient, humoral response to the vector. Compared with control subjects, the measured rates of decline of all MRI parameters were slower, albeit the numbers were too small for statistical significance. Importantly, assessment of the neurologic rating scale, which was the primary outcome variable, demonstrated a significantly reduced rate of decline compared with control subjects. Although the trial is not matched, randomized, or blinded and lacked a contemporaneous placebo/sham control group, assessment of the primary outcome variable suggests a slowing of progression of LINCL in the treated children. On this basis, we propose that additional studies to assess the safety and efficacy of AAVmediated gene therapy for LINCL are warranted.

Original languageEnglish
Pages (from-to)463-474
Number of pages12
JournalHuman Gene Therapy
Volume19
Issue number5
DOIs
Publication statusPublished - 1 May 2008
Externally publishedYes

Fingerprint

Neuronal Ceroid-Lipofuscinoses
Dependovirus
Complementary DNA
Magnetic Resonance Imaging
Lysosomal Storage Diseases
Safety
Status Epilepticus
Therapeutics
Genetic Therapy
Nervous System
Placebos
Outcome Assessment (Health Care)
Inflammation
Control Groups
Serogroup

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. / Worgall, Stefan; Sondhi, Dolan; Hackett, Neil R.; Kosofsky, Barry; Kekatpure, Minal V.; Neyzi, Nurunisa; Dyke, Jonathan P.; Ballon, Douglas; Heier, Linda; Greenwald, Bruce M.; Christos, Paul; Mazumdar, Madhu; Souweidane, Mark M.; Kaplitt, Michael G.; Crystal, Ronald.

In: Human Gene Therapy, Vol. 19, No. 5, 01.05.2008, p. 463-474.

Research output: Contribution to journalArticle

Worgall, S, Sondhi, D, Hackett, NR, Kosofsky, B, Kekatpure, MV, Neyzi, N, Dyke, JP, Ballon, D, Heier, L, Greenwald, BM, Christos, P, Mazumdar, M, Souweidane, MM, Kaplitt, MG & Crystal, R 2008, 'Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA', Human Gene Therapy, vol. 19, no. 5, pp. 463-474. https://doi.org/10.1089/hum.2008.022
Worgall, Stefan ; Sondhi, Dolan ; Hackett, Neil R. ; Kosofsky, Barry ; Kekatpure, Minal V. ; Neyzi, Nurunisa ; Dyke, Jonathan P. ; Ballon, Douglas ; Heier, Linda ; Greenwald, Bruce M. ; Christos, Paul ; Mazumdar, Madhu ; Souweidane, Mark M. ; Kaplitt, Michael G. ; Crystal, Ronald. / Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. In: Human Gene Therapy. 2008 ; Vol. 19, No. 5. pp. 463-474.
@article{e470ea1fe13c49c6adffd7a138da77af,
title = "Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA",
abstract = "Late infantile neuronal ceroid lipofuscinosis (LINCL) is an autosomal recessive, neurodegenerative lysosomal storage disease affecting the CNS and is fatal by age 8 to 12 years. A total average dose of 2.5 × 1012 particle units of an adeno-associated virus (AAV) serotype 2 vector expressing the human CLN2 cDNA (AAV2CU hCLN2) was administered to 12 locations in the CNS of 10 children with LINCL. In addition to safety parameters, a neurological rating scale (primary variable) and three quantitative magnetic resonance imaging (MRI) parameters (secondary variables) were used to compare the rate of neurological decline for 18 months in treated subjects compared with untreated subjects. Although there were no unexpected serious adverse events that were unequivocally attributable to the AAV2CU hCLN2 vector, there were serious adverse effects, the etiology of which could not be determined under the conditions of the experiment. One subject died 49 days postsurgery after developing status epilepticus on day 14, but with no evidence of CNS inflammation. Four of the 10 subjects developed a mild, mostly transient, humoral response to the vector. Compared with control subjects, the measured rates of decline of all MRI parameters were slower, albeit the numbers were too small for statistical significance. Importantly, assessment of the neurologic rating scale, which was the primary outcome variable, demonstrated a significantly reduced rate of decline compared with control subjects. Although the trial is not matched, randomized, or blinded and lacked a contemporaneous placebo/sham control group, assessment of the primary outcome variable suggests a slowing of progression of LINCL in the treated children. On this basis, we propose that additional studies to assess the safety and efficacy of AAVmediated gene therapy for LINCL are warranted.",
author = "Stefan Worgall and Dolan Sondhi and Hackett, {Neil R.} and Barry Kosofsky and Kekatpure, {Minal V.} and Nurunisa Neyzi and Dyke, {Jonathan P.} and Douglas Ballon and Linda Heier and Greenwald, {Bruce M.} and Paul Christos and Madhu Mazumdar and Souweidane, {Mark M.} and Kaplitt, {Michael G.} and Ronald Crystal",
year = "2008",
month = "5",
day = "1",
doi = "10.1089/hum.2008.022",
language = "English",
volume = "19",
pages = "463--474",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA

AU - Worgall, Stefan

AU - Sondhi, Dolan

AU - Hackett, Neil R.

AU - Kosofsky, Barry

AU - Kekatpure, Minal V.

AU - Neyzi, Nurunisa

AU - Dyke, Jonathan P.

AU - Ballon, Douglas

AU - Heier, Linda

AU - Greenwald, Bruce M.

AU - Christos, Paul

AU - Mazumdar, Madhu

AU - Souweidane, Mark M.

AU - Kaplitt, Michael G.

AU - Crystal, Ronald

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Late infantile neuronal ceroid lipofuscinosis (LINCL) is an autosomal recessive, neurodegenerative lysosomal storage disease affecting the CNS and is fatal by age 8 to 12 years. A total average dose of 2.5 × 1012 particle units of an adeno-associated virus (AAV) serotype 2 vector expressing the human CLN2 cDNA (AAV2CU hCLN2) was administered to 12 locations in the CNS of 10 children with LINCL. In addition to safety parameters, a neurological rating scale (primary variable) and three quantitative magnetic resonance imaging (MRI) parameters (secondary variables) were used to compare the rate of neurological decline for 18 months in treated subjects compared with untreated subjects. Although there were no unexpected serious adverse events that were unequivocally attributable to the AAV2CU hCLN2 vector, there were serious adverse effects, the etiology of which could not be determined under the conditions of the experiment. One subject died 49 days postsurgery after developing status epilepticus on day 14, but with no evidence of CNS inflammation. Four of the 10 subjects developed a mild, mostly transient, humoral response to the vector. Compared with control subjects, the measured rates of decline of all MRI parameters were slower, albeit the numbers were too small for statistical significance. Importantly, assessment of the neurologic rating scale, which was the primary outcome variable, demonstrated a significantly reduced rate of decline compared with control subjects. Although the trial is not matched, randomized, or blinded and lacked a contemporaneous placebo/sham control group, assessment of the primary outcome variable suggests a slowing of progression of LINCL in the treated children. On this basis, we propose that additional studies to assess the safety and efficacy of AAVmediated gene therapy for LINCL are warranted.

AB - Late infantile neuronal ceroid lipofuscinosis (LINCL) is an autosomal recessive, neurodegenerative lysosomal storage disease affecting the CNS and is fatal by age 8 to 12 years. A total average dose of 2.5 × 1012 particle units of an adeno-associated virus (AAV) serotype 2 vector expressing the human CLN2 cDNA (AAV2CU hCLN2) was administered to 12 locations in the CNS of 10 children with LINCL. In addition to safety parameters, a neurological rating scale (primary variable) and three quantitative magnetic resonance imaging (MRI) parameters (secondary variables) were used to compare the rate of neurological decline for 18 months in treated subjects compared with untreated subjects. Although there were no unexpected serious adverse events that were unequivocally attributable to the AAV2CU hCLN2 vector, there were serious adverse effects, the etiology of which could not be determined under the conditions of the experiment. One subject died 49 days postsurgery after developing status epilepticus on day 14, but with no evidence of CNS inflammation. Four of the 10 subjects developed a mild, mostly transient, humoral response to the vector. Compared with control subjects, the measured rates of decline of all MRI parameters were slower, albeit the numbers were too small for statistical significance. Importantly, assessment of the neurologic rating scale, which was the primary outcome variable, demonstrated a significantly reduced rate of decline compared with control subjects. Although the trial is not matched, randomized, or blinded and lacked a contemporaneous placebo/sham control group, assessment of the primary outcome variable suggests a slowing of progression of LINCL in the treated children. On this basis, we propose that additional studies to assess the safety and efficacy of AAVmediated gene therapy for LINCL are warranted.

UR - http://www.scopus.com/inward/record.url?scp=44349136847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44349136847&partnerID=8YFLogxK

U2 - 10.1089/hum.2008.022

DO - 10.1089/hum.2008.022

M3 - Article

VL - 19

SP - 463

EP - 474

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 5

ER -